In these lines, it is tempting to suggest that the Gαq-biased properties of the ERK5 pathway could further our understanding of angiotensin II-promoted cardiac hypertrophy, where this pathway was recently shown to be relevant [9], and potentially contribute to the fine tuning of therapeutic interventions. Here, MAPK7 is linked to cardiac hypertrophy.